27 September 2023
27 September 2023
Alfasigma will gain access to Intercept’s Ocaliva, which is indicated for treating primary biliary cholangitis.
Coherus has also announced the completion of study site inspections by the FDA for the checkpoint inhibitor toripalimab.
CSL will use its existing manufacturing facility in Liverpool to produce the vaccines if a pandemic is declared by the WHO.
The Sandoz biosimilar, Tyruko, has been approved for all indications, including MS and Crohn’s, as the reference medication, Biogen’s Tysabri.
As part of the expanded deal, the CF Foundation will increase its funding to $25m.
Both facilities offer mRNA services at all scales and applications, from pre-clinical to commercial.
The funding will support the clinical development of the oral SK ion channel inhibitor that was recently evaluated in a Phase II trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.
Give your business an edge with our leading industry insights.
